EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

on behalf of the EANO Executive Board and ESMO Guidelines Committee

doi:10.1093/annonc/mdx221

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

on behalf of the EANO Executive Board and ESMO Guidelines Committee

Research related

Research output: Contribution to journal › Article › peer-review

320 Citations (Scopus)

Original language	English
Pages (from-to)	iv84-iv99
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/annonc/mdx221
Publication status	Published - 2017

Access to Document

10.1093/annonc/mdx221

Cite this

@article{5fe98f49392a427284dd84455f491f8c,

title = "EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours",

author = "{on behalf of the EANO Executive Board and ESMO Guidelines Committee} and {Le Rhun}, E. and M. Weller and D. Brandsma and {Van den Bent}, M. and {de Azambuja}, E. and R. Henriksson and T. Boulanger and S. Peters and C. Watts and W. Wick and P. Wesseling and R. Rud{\`a} and M. Preusser",

note = "Funding Information: ELR has received research support from Mundipharma and Amgen. MW has received research grants from Acceleron, Actelion, Bayer, Isarna, MSD, Merck EMD, Novocure, Piqur and Roche and honoraria for lectures or advisory board participation or consulting from Bristol-Myers Squibb, Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck EMD, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva and Tocagen. MVdB has received research support from BBB therapeutics. EdA has received advisory board from Roche; travels grant from Roche and GlaxoSmithKline; research grant from Roche. WW has received research support from Pfizer, Apogenix, MSD and Roche and has reported being a member of the speaker{\textquoteright}s bureau of Brystol-Myers Squibb and MSD. MP has received research support from B{\"o}hringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and AstraZeneca. DB, RH, TB, SP, CW, WW, PW and RR have declared no potential conflicts of interest.",

year = "2017",

doi = "10.1093/annonc/mdx221",

language = "English",

volume = "28",

pages = "iv84--iv99",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

AU - on behalf of the EANO Executive Board and ESMO Guidelines Committee

AU - Le Rhun, E.

AU - Weller, M.

AU - Brandsma, D.

AU - Van den Bent, M.

AU - de Azambuja, E.

AU - Henriksson, R.

AU - Boulanger, T.

AU - Peters, S.

AU - Watts, C.

AU - Wick, W.

AU - Wesseling, P.

AU - Rudà, R.

AU - Preusser, M.

N1 - Funding Information: ELR has received research support from Mundipharma and Amgen. MW has received research grants from Acceleron, Actelion, Bayer, Isarna, MSD, Merck EMD, Novocure, Piqur and Roche and honoraria for lectures or advisory board participation or consulting from Bristol-Myers Squibb, Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck EMD, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva and Tocagen. MVdB has received research support from BBB therapeutics. EdA has received advisory board from Roche; travels grant from Roche and GlaxoSmithKline; research grant from Roche. WW has received research support from Pfizer, Apogenix, MSD and Roche and has reported being a member of the speaker’s bureau of Brystol-Myers Squibb and MSD. MP has received research support from Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche and AstraZeneca. DB, RH, TB, SP, CW, WW, PW and RR have declared no potential conflicts of interest.

PY - 2017

Y1 - 2017

UR - http://www.scopus.com/inward/record.url?scp=85029700919&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx221

DO - 10.1093/annonc/mdx221

M3 - Article

C2 - 28881917

AN - SCOPUS:85029700919

SN - 0923-7534

VL - 28

SP - iv84-iv99

JO - Annals of Oncology

JF - Annals of Oncology

ER -